Skip to main content
Clinical Trials/CTRI/2020/11/028803
CTRI/2020/11/028803
Not yet recruiting
未知

A prospective study to evaluate the bacteriological and antigen-specific immunological responses induced by MIP and/ BCG vaccines as adjunctive treatment (immunotherapy) in multibacillary leprosy patients treated with multidrug therapy

ICMR0 sites0 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Health Condition 1: A304- Borderline lepromatous leprosyHealth Condition 2: A303- Borderline leprosyHealth Condition 3: A302- Borderline tuberculoid leprosyHealth Condition 4: A305- Lepromatous leprosy
Sponsor
ICMR
Status
Not yet recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
ICMR

Eligibility Criteria

Inclusion Criteria

  • 1\. Treatment naïve cases of MB leprosy classified according to WHO classification.
  • 2\. Age group: 12\- 60 years
  • 3\. Patients willing to give consent (for patients aged 12\-18years willing to give assent and consent from the legally acceptable representative)

Exclusion Criteria

  • Paucibacillary (PB) cases of leprosy
  • 2\. Defaulter cases
  • 3\. Relapse cases
  • 4\. Patients on steroids\- prednisolone dose \>20mg/day for more than 2 weeks
  • 5\. Pregnancy or breast feeding
  • 6\. With medical co\-morbidities like diabetes, cancer, history of or active pulmonary tuberculosis
  • 7\. People living with HIV/AIDS

Outcomes

Primary Outcomes

Not specified

Similar Trials